Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches

After agreeing to swallow Celgene for a whopping $74 billion, Bristol-Myers Squibb trumpeted the idea that pairing its solid-tumor expertise with Celgene’s hematology expertise could create a leading cancer drugmaker. But the legacy BMS business had some hematology expertise of its own—and Celgene's taking advantage.